NEW YORK, Nov. 14, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=111741&from=4CLASS PERIOD: Febru ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=111428&from=3 CLASS PERIO ...

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is Dece ...

Lawsuit Overview - Edwards Lifesciences Corporation is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 during the Class Period from February 6, 2024, to July 24, 2024 [1] - The lawsuit claims that the company and certain executives made false or misleading statements regarding revenue outlook, growth projections, and risks related to its core product, Transcatheter Aortic Valve Replacement (TAVR) [4] - On July 24, 2024, Edwards Lifesciences disclosed disappointing Q2 2024 TAVR results and lowered its fiscal year 2024 projections, leading to a 31% drop in stock price [5] Product and Market Context - Edwards Lifesciences specializes in products and technologies for structural heart disease and critical care monitoring, with TAVR being one of its core products [3] - The lawsuit alleges that the company overstated hospital interest in continuing to use TAVR over newer, innovative structural heart therapies [4] Financial Impact - The company's optimistic reports on TAVR growth and anticipated ramp in Q2 2024 and throughout fiscal year 2024 fell short of expectations due to failed "patient activation activities" [4] - The stock price decline of more than 31% on July 24, 2024, reflects the market's reaction to the disappointing TAVR results and revised projections [5] Legal Process - Investors who purchased or acquired Edwards Lifesciences securities during the Class Period have until December 13, 2024, to seek appointment as lead plaintiff in the class action lawsuit [1] - The lead plaintiff will represent all class members and can select a law firm to litigate the case, with the ability to share in any potential future recovery not dependent on serving as lead plaintiff [6]

NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

SAN DIEGO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Edwards Lifesciences Corporation (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Class Period”), have until Friday, December 13, 2024 to seek appointment as lead plaintiff of the Edwards Lifesciences class action lawsuit. Captioned Patel v. Edwards Lifesciences Corporation, No. 24-cv-02221 (C.D. Cal.), the Edwards Lifesciences class action lawsuit charges ...

NEW YORK, Nov. 7, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW).Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=110877&from=4CLASS PERIOD: Februa ...

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Edwards Lifesciences Corp (“Edwards” or the “Company”) (NYSE: EW) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, both dates inclusive (the “Class Period”). Inve ...